Notice of Intent to Publish a Funding Opportunity Announcement for Turkey-US Collaborative Program for Affordable Medical Technologies (R01)

Notice Number: NOT-CA-15-021

Key Dates
Release Date: May 8, 2015
Estimated Publication Date of Announcement: June 2015
First Estimated Application Due Date: October 2015
Earliest Estimated Award Date: April 2016
Earliest Estimated Start Date: April 2016

Related Announcements
None

Issued by
National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications from research partnership between U.S. and Turkish scientists to promote the development of appropriate affordable diagnostic and therapeutic technologies to address medical needs in low-middle resource settings. Appropriate medical technologies are those that are useable, cost effective, sustainable, and effective in meeting a significant clinical needs in a lower-middle resource setting in different world regions.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in the summer of 2015 with an expected application due date in the fall of 2015.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

This Notice encourages the collaboration between US and Turkish investigators to develop new affordable diagnostic and therapeutic technologies for lower-middle resource settings, and enable product development and/or technology transfer. The goals of this FOA are to:

  • Foster joint activities between U.S. and Turkish scientists on affordable detection, diagnostic and therapeutic technologies.
  • Address medical needs in low-middle resource settings, and take advantage of opportunities and technological advances, with the development of appropriate and affordable medical devices.

Emphasis will be placed on technologies that increase healthcare access, cancer care and control, address global health disparities and/or address the diagnosis and treatment of diseases of the poor and underserved populations. Examples may include, but are not restricted to the following:

  • Quantitative tools for monitoring therapy, treatment response, screening for post-therapeutic relapse and pre-clinical models for research;
  • Low-cost technologies that help collect robust patient-reported outcomes information to support clinical research efforts;
  • Technologies that can be used in conjunction with imaging to improve sensitivity and specificity of early cancer detection;
  • Low-cost molecular detection technologies for risk and survival assessment utilizing biospecimens collected by non-invasive or minimally invasive methods, and archived biospecimens.
  • Low cost imaging technologies for risk and survival assessment
  • Low-cost technologies for the collection and stabilization/preservation of patient biospecimens for transport for subsequent diagnostic analysis;
  • Low-cost technologies that improve quality, accuracy, reproducibility and reliability of immuno-histochemical detection/diagnosis;
  • Low cost technologies for assessment of minimal residual disease;
  • Low cost technologies for non-invasive or minimally invasive diagnosis;
  • Point-of-care tests and reagents for cancer detection and diagnosis;
  • Networked and mobile technologies for diagnostic devices mHealth;
  • Appropriate, low-cost diagnostic imaging devices for low-resource settings;
  • Non-invasive or minimally-invasive screening, detection and diagnostics technologies (e.g. low-cost imaging, biosensors, microfluidics, and microchip technologies);
  • Development of low-cost diagnostic assay kits;
  • Low-cost multiplex diagnostic technology platforms.

APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.

Inquiries

Please direct all inquiries to:

Miguel Ossandon
National Cancer Institute (NCI)
Telephone: 240-276-5714
Email: ossandom@mail.nih.gov